CHARACTERISTICS AND POTENTIAL THERAPEUTIC APPLICATIONS OF DENDRITIC CELLS, ANTIGEN SPECIFIC MODULATORS OF IMMUNE RESPONSES
Abstract
Background. Since the discovery of dendritic cells (DC) more than 30 years ago, several types of DC have been isolated in mouse and human and methods for their in vitro generation have been developed. Their general characteristics are, the extensive expression of MHC class II molecules on their cell surfaces, the ability to take up, process and present antigens, selective migration through tissues and interaction with lymphocytes. Once they were reknown for their stimulatory role in T cell proliferation and CTL generation but tolerogenic types have since been described which contribute to the maintenance of tolerance to self antigens. Cructial for the defence against pathogens are Langerhans cells and dermal or interstitial DC that reside in the peripheral tissues and take up antigens. Then they migrate to lymph nodes or spleen and present the antigens to T cells. If infectious or inflammatory signals/factors are present in the periphery, DC begin to express costimulatory molecules and secrete cytokines which enable them to trigger immune response, and in addition, influence its characteristics and shape the effector mechanisms.
Conclusions. There is a great hope that in the near future ex vivo differentiated DC, equipped with selected antigens could be used for the treatment of cancer, autoimmune diseases and for the prevention of rejections following tissue and organ transplantations.
Downloads
References
Janeway CA, Travers P, Walport M, Shlomchik MJ. Immunobiology. The immune system in health and disease. 5th ed. New York: Garland Publishing, 2001: 294–340.
Romani N, Holzmann S, Tripp CH, Koch F, Stoitzner P. Langerhans cells – dendritic cells of the epidermis. AMPIS 2003; 111: 725–40.
Schuler G, Steinman RM. Murine epidermal langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J Exp Med 1985; 161: 526– 46.
Steinman RM in Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantititation; tissue distribution. J Exp Med 1973; 137: 1142–62.
Steinman RM in Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro. J Exp Med 1974; 139: 380–97.
Steinman RM in Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. III. Functional properties in vivo. J Exp Med 1974; 139: 1431–5.
Steinman RM in Witmer MD. Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc Natl Acad sci, 1978; 75: 5132–6.
Romani N, Gruner S, Brang D et al. Proliferating dendritic cells progenitors in human blood. J Exp Med 1994; 180: 83–93.
Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granuolcyte/macrophage colony-stimulating factor plus interlevkin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109–18.
Hart DNJ, MacDonald K, Vuckovic S, Clark GJ. Phenotypic characterization of dendritic cells. Dendritic Cells. Biology and clinical applications. 2nd ed. London: Academic Press, 2001.
Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001; 106: 259–62.
Steinman RM. Some interfaces of dendritic cell biology. AMPIS 2003; 111: 675–97.
Repnik U, Knezevic M, Jeras M. Simple and cost-effective isolation of monocytes from buffy coats. JIM 2003; 278: 283–92.
Austyn JM. Dendritic cells – new therapeutic targets. Isis News 2001; 34: 2–4.
Kalinski P, Hilkens CMU, Wierenga EA, Kapsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunology Today 1999, 20: 561–7.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
